Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SV-202
- Development stage
- Preclinical
- Lead developer
- Kangweizhonghe
- Modality
- Antibody-Based Therapeutics
01
Overview
SV-202 is a preclinical-stage therapeutic candidate being developed by Kangweizhonghe Biopharmaceutical for the treatment of leukemia. It is designed to target the B-lymphocyte antigen CD20, a protein expressed on the surface of both normal and malignant B-cells. While the specific molecular modality has not been explicitly disclosed in early pipeline reports, CD20-targeting agents in biopharmaceutical development are typically monoclonal antibodies or related biologics intended to induce cell death in cancerous B-lymphocytes through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).
- Other names
- CD20 nanobodyCD-20 nanobodyCD 20 nanobody纳米抗体
02
Targets
Beyond the preview
Go deeper on SV-202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SV-202.